BENEFICIAL EFFECTS OF INCREASING LOCAL BLOOD FLOW

• US 20110028548A1
• Filed: 10/08/2010
• Published: 02/03/2011
• Est. Priority Date: 04/19/2004
• Status: Abandoned Application

• Current Assignee: Strategic Science & Technologies, LLC
• Original Assignee: Strategic Science & Technologies, LLC
• Inventors: Fossel, Eric Thor
• Application Number:
  US12/901,306
• Publication Number:
  US 20110028548A1
• Time in Patent Office: Days
• US Class Current: 514/551
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 33/14 Alkali metal chlorides; Alkaline earth metal chlorides
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/183 Amino acids, e.g. glycine, EDTA or aspartame
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood. Examples of conditions which may benefit from increased blood flow include, but are not limited to, erectile dysfunction, hair loss, female sexual dissatisfaction, sagging facial or other body tissue, peripheral vascular disease including claudication, neuropathy, skin ulcers, bone healing, wound healing, viral and bacterial infection, and skin grafting.

Claims

1-40. -40. (canceled)

41. A method of treating a subject having diabetes, wherein the subject is in need of improvement of blood circulation within a foot, the method comprising:

administering, to the foot of a subject diagnosed as having diabetes, a cream defining a hostile biophysical environment therein having an ionic strength of at least about 0.25 M, wherein the hostile biophysical environment within the cream contains L-arginine and/or L-arginine hydrochloride.

42. The method of claim 41, wherein the hostile biophysical environment has an ionic strength of at least about 1 M.

43. The method of claim 41, wherein the L-arginine and/or L-arginine hydrochloride is present at a concentration of between about 0.05% and about 25% by weight.

44. The method of claim 41, wherein the hostile biophysical environment comprises one or more of sodium chloride, choline chloride, magnesium chloride, or calcium chloride.

45. A method of treating a subject having diabetes, wherein the subject is in need of improvement of blood circulation within a foot, the method comprising:

administering, to the foot of a subject diagnosed as having diabetes, a cream defining a hostile biophysical environment therein having an ionic strength of at least about 0.25 M, wherein the hostile biophysical environment within the cream contains a nitric oxide donor.

46. The method of claim 45, wherein the nitric oxide donor has a concentration of between about 0.05% and about 25% by weight.

47. The method of claim 45, wherein the nitric oxide donor comprises a derivative of L-arginine.

48. The method of claim 45, wherein the nitric oxide donor comprises L-arginine methyl ester.

49. The method of claim 45, wherein the nitric oxide donor comprises L-arginine butyl ester.

50. The method of claim 45, wherein the hostile biophysical environment has an ionic strength of at least about 1 M.

51. The method of claim 45, wherein the hostile biophysical environment comprises one or more of sodium chloride, choline chloride, magnesium chloride, calcium chloride.

52. A method of treating a subject having impaired circulation in a foot, the method comprising:

administering, to the foot of a subject, a cream comprising a nitric oxide donor, the cream defining a hostile biophysical environment therein having an ionic strength of at least about 0.25 M.

53. The method of claim 52, wherein the hostile biophysical environment has an ionic strength of at least about 1 M.

54. The method of claim 52, wherein the nitric oxide donor comprises L-arginine.

55. The method of claim 52, wherein the nitric oxide donor comprises L-arginine hydrochloride.

56. The method of claim 52, wherein the nitric oxide donor comprises a derivative of L-arginine.

57. The method of claim 52, wherein the nitric oxide donor comprises L-arginine methyl ester.

58. The method of claim 52, wherein the nitric oxide donor comprises L-arginine butyl ester.

59. The method of claim 52, wherein the hostile biophysical environment comprises one or more of sodium chloride, choline chloride, magnesium chloride, calcium chloride.